Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis - Takeaways - MDSpire

Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis

  • By

  • Mohammed Elmujtba Adam Essa

  • Hamid Noori

  • James Butler

  • Abdelkareem A. Ahmed

  • February 21, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors have improved outcomes in advanced non-small cell lung cancer and melanoma but face challenges like resistance and adverse events.

  • 2

    The gut microbiome significantly influences immune responses and the efficacy of cancer immunotherapy, particularly immune checkpoint inhibitors.

  • 3

    Patients with melanoma and NSCLC who respond to anti-PD-1 therapy show a more diverse gut microbiome compared to non-responders.

  • 4

    Specific beneficial bacteria, such as Faecalibacterium and Akkermansia muciniphila, are associated with improved responses to immunotherapy.

  • 5

    This systematic review and meta-analysis aims to evaluate the relationship between gut microbiome characteristics and clinical outcomes in cancer patients treated with ICIs.

Original Source(s)

Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis

  • by Mohammed Elmujtba Adam Essa, Hamid Noori, James Butler, Abdelkareem A. Ahmed

  • February 21, 2026

Related Content

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

Multiple ground-glass nodules after lobectomy for multiple primary lung cancer: a case report

Unmasking the “targetless” illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report